(Q37740452)

22 August 2017

1 reference

title

Impact of different long-term maintenance immunosuppressive therapy strategies on patients' outcome after heart transplantation (English)

1 reference

22 August 2017

4

Roland Hetzer

1 reference

22 August 2017

3

Christoph Knosalla

1 reference

22 August 2017

1

Michael Dandel

1 reference

PubMed ID

20434559

22 August 2017

Hans Brendan Lehmkuhl

series ordinal

2

object named as

Hans Brendan Lehmkuhl

1 reference

22 August 2017

29 April 2010

1 reference

22 August 2017

Transplant Immunology

1 reference

22 August 2017

23

1 reference

22 August 2017

3

1 reference

22 August 2017

93-103

1 reference

Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report--2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Daclizumab to prevent rejection after cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients--a large European trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

The changing face of heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Long-term results of tacrolimus monotherapy in cardiac transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Maintenance immunosuppression with mycophenolate mofetil: long-term efficacy and safety after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Mycophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplant patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Long-term benefits of mycophenolate mofetil after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

From mechanisms to long-term benefits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Cardiac allograft vasculopathy: recent developments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Changing trends in infectious disease in heart transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Calcineurin inhibitors in heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Calcineurin-inhibitor minimization protocols in heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Proliferation signal inhibitors and cardiac allograft vasculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Chronic renal failure after transplantation of a nonrenal organ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients--the IMPROVED multi-centre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Benefit of mycophenolate-mofetil (MMF) in patients with cyclosporine (CYA) induced nephropathy after cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Do cardiovascular risk factors influence cardiac allograft vasculopathy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Immunosuppressive therapy in older cardiac transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Hypertension after pediatric heart transplantation is primarily associated with immunosuppressive regimen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Heart transplant recipient clinical profile improvement following mycophenolate mofetil late incorporation into the treatment schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Preliminary experience with mycophenolate mofetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Renal protective strategies in heart transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Low-dose tacrolimus/sirolimus and steroid withdrawal in heart recipients is highly efficacious

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Minimization of immunosuppression: transplant immunology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Outcomes following de novo CNI-free immunosuppression after heart transplantation: a single-center experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Steroid use in heart transplant patients in Spain in the current era: a multicenter survey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Long-term follow-up of pediatric cardiac transplant recipients on a steroid-free regime: the role of endomyocardial biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Pediatric cardiac transplant: results using a steroid-free maintenance regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Safety and early outcomes using a corticosteroid-avoidance immunosuppression protocol in pediatric heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.04.007

10.1016/J.TRIM.2010.04.007

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20434559